# PhII Study STA-9090 as Second or Third-Line Therapy for Metastatic Pancreas Cancer

> **NCT01227018** · PHASE2 · TERMINATED · sponsor: **Vanderbilt-Ingram Cancer Center** · enrollment: 15 (actual)

## Conditions studied

- Adenocarcinoma of the Pancreas
- Recurrent Pancreatic Cancer
- Stage IV Pancreatic Cancer

## Interventions

- **DRUG:** STA-9090
- **RADIATION:** Radiologic imaging
- **PROCEDURE:** blood draw

## Key facts

- **NCT ID:** NCT01227018
- **Lead sponsor:** Vanderbilt-Ingram Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-12
- **Primary completion:** 2013-05
- **Final completion:** 2013-05
- **Target enrollment:** 15 (ACTUAL)
- **Why stopped:** interim analysis found the study drug to be ineffective
- **Last updated:** 2014-07-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01227018

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01227018, "PhII Study STA-9090 as Second or Third-Line Therapy for Metastatic Pancreas Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01227018. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*